Author: [email protected]

Release – Century Lithium Sets Date For 2026 Annual General Meeting And Announces Director Slate And New Nominee Dr. Cormac O’Laoire

Posted on by [email protected]

October 27, 2026 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or the “Company”) is pleased to announce its Annual General Meeting of Shareholders (the “Meeting”) will be held on November 25, 2026. During the Meeting, the management will nominate five directors for election to the Company’s Board of Directors (the “Board”), Dr. Corby Anderson, Dr. William Willoughby, Donald Myers, James Pettit and Dr. Cormac O’Laoire, who stands for election for the first time. Bryan Disher is retiring from the Board and will not stand for re-election; he will continue to serve as a director through the conclusion of the Meeting.

Dr. O’Laoire has worked closely with management as a Strategic Advisor since January 2026, and his depth in battery materials, gigafactory execution and lender due diligence bears directly on the decisions ahead as Century Lithium moves Angel Island through permitting and into project finance.

The Board would like to thank Mr. Disher for his many contributions to Century Lithium and for his continued service through the Meeting.

New Director Nominee

Cormac O’Laoire, PhD is Managing Director of Electrios Ltd., a Hong Kong-based battery advisory firm, and has served as Strategic Advisor to Century Lithium since January 2026. He has over 20 years of experience across the lithium-ion battery value chain, from battery metals and lithium refining through precursor and cathode active materials (pCAM/CAM), cell manufacturing, energy storage and recycling.

Based in Hong Kong for more than a decade, Dr. O’Laoire has advised automakers, cell manufacturers, materials suppliers, governments, lenders, and investors on battery manufacturing, materials processing and battery energy storage projects, providing technical due diligence, lenders’ technical advisory, capital-cost review and independent oversight for more than 60 GWh of capacity. He is also a retained expert witness in industrial litigation and international arbitration.

Dr. O’Laoire began his career in electrochemical research, including as a Postdoctoral Fellow at Lawrence Berkeley National Laboratory, a US Department of Energy national laboratory, and his doctoral research on lithium-air battery chemistry is widely cited. He holds a PhD in Physical Chemistry from Northeastern University in Boston, Massachusetts.

Information concerning the Meeting and the procedures for voting will be included in the Company’s Notice of Meeting and Management Information Circular, which will be filed under the Company’s profile on SEDAR+ in advance of the Meeting. Shareholders are encouraged to review the meeting materials when available and to vote their shares.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced-stage lithium development company focused on its 100%-owned Angel Island Lithium Project in Esmeralda County, Nevada. Angel Island hosts one of the largest known sedimentary lithium deposits in the United States and is designed with an integrated, end-to-end process to produce battery-grade lithium carbonate on-site to support the electric vehicle and battery storage markets.

The Company has developed a patent-pending process that incorporates hydrochloric acid leaching combined with direct lithium extraction to produce battery-grade lithium carbonate. As part of the integrated chlor-alkali process, Angel Island is designed to produce sodium hydroxide as a co-product, with planned surplus sales expected to lower operating costs, reduce reliance on externally sourced reagents, and minimize environmental impacts.

Century Lithium is currently advancing Angel Island through the permitting process.

Century Lithium trades on the TSX Venture Exchange under the symbol “LCE”, the OTCQX under the symbol “CYDVF” and on the Frankfurt Stock Exchange under the symbol “C1Z”. To learn more, please visit centurylithium.com.

ON BEHALF OF CENTURY LITHIUM CORP.
WILLIAM WILLOUGHBY, PhD, PE
President & Chief Executive Officer
For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
[email protected]
centurylithium.com

Release – As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated – Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides

Posted on by [email protected]

Shelton, Connecticut – Tuesday, October 27, 2026.


NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage leader
developing antiviral drugs that viruses cannot escape, explained today that the Phase IIA Ebola Treatment
Clinical Trial of NV-387 Oral Gummies is progressing well, and the drug is expected to advance into the
Phase IIB clinical trial part as soon as the Phase IIA part is completed.

“The importance of the NV-387 Oral Gummies treatment for this Ebola Bundibugyo virus disease
cannot be understated, considering the potential of the disease for rapid spread and the heavy toll it is
taking in affected areas in terms of both deaths and economic costs of containment and response,” said
Anil R. Diwan, PhD, President and Executive Chairman of the Company.

The NV-387 Oral Gummies as a Treatment for Ebola Phase II Clinical Trial in DRC is divided
into two parts. The first part, Phase IIA, is designed to evaluate dosing regimens based on the severity of
the disease, and requires approximately 20 patients. Enrollment began on September, 23, 2026. The end
point is 28-day survival, as with other Ebola clinical trials. As such, the Phase IIA part will be completed
once the last enrolled person completes 28 days.

The course of the clinical trial suggests that the trial will continue into Phase IIB part upon completion of
the Phase IIA part.

Ebola has escaped the main epidemic affected country of Democratic Republic Congo (DRC) in
multiple instances, and cases have started occurring in Kenya as well as Nigeria, one of the most
populous countries in Africa . Previously, an infected person had traveled from DRC to Uganda, causing 1
a small outbreak, but there have been no new cases reported in Uganda recently. A person that traveled
recently from DRC to Kenya died, and infected at least 8 others, one of whom has also died, and at least
134 contacts were traced . Kenya has released some of the quarantined contacts. The case in Nigeria was 2
a Swiss national and was evacuated to a Swiss hospital for treatment. Previously, medical personnel
working with the Doctors Without Borders (MSF/DWB) have been evacuated to Europe for treatment.

This East to West Africa spread has occurred in spite of substantive travel restrictions. Additional
restrictions have been effected by many countries as a result . Importantly, the instances of single 3
infected persons creating multiple cases have demonstrated the significant global risk and challenge posed
by this Ebola outbreak. As many as 8 or more cases have occurred from contact with a single infected
person during this outbreak. Such persons causing a large number of transmissions are often called
“superspreaders”.

As the outbreak continues, the number of confirmed cases in DRC have reached 10,060, with
4,887 deaths since this Ebola-Bundibugyo virus outbreak was identified. It is the fastest growing Ebola
outbreak, and largest in DRC, with the potential to eclipse, in a few months, the West Africa 2014-16
Ebola-Zaire outbreak that killed 11,000 people.

A clinical trial of Infusions of an antibody cocktail, Infusion of remdesivir, and Infusion of both
of them given to the patient is in progress, called the “PARTNERS” clinical trial, since July 2, 2026.
There have been no public updates, other than that more than 350 patients were already enrolled about a
month ago.

A clinical trial to evaluate vaccines, called “Tumaini” (meaning “Hope” in Swahili) has started as
of last week. The first candidate vaccine in this trial is Ervebo, which is specific to Ebola Zaire, and it is
not known how effective it could be against Ebola Bundibugyo virus. Two other vaccine candidates, one
developed by University of Oxford, ChAdOx1-BDBV, and another, a BDBV-mRNA vaccine developed
by Moderna, are expected to be added into this clinical trial when the supplies become available . This 4
vaccines trial will employ a “ring vaccination” protocol.

Ervebo vaccine is not specific to BDBV, which means it is an unmatched vaccine. Unmatched
Page 1 of 4vaccines can cause rapid occurrence of escape mutants. Also, in vaccinated persons, later infection can
even cause a more aggressive disease, a phenomenon called “Antibody-Dependent Enhancement” of
disease, promoted by the inaccurate antibodies created in response to the vaccine. Vaccines in general can
lead to escape mutants. Ebola virus is an RNA virus and thus very capable of generating escape mutants.
Vaccines are not useful for a person after infection. Also, a vaccine requires about 2-3 weeks for
antibody response to be generated, and therefore is minimally protective before 3 weeks. If a second dose
of vaccine is needed, it complicates the situation further, because the first dose only creates partial
immunity.

Thus an effective treatment is essential for combatting a spreading epidemic such as the current
Ebola epidemic. Infusions such as of antibody cocktails or small chemical drugs are only useful, if
effective, when patients can be hospitalized for the duration until recovery, and are costly to store,
transport, and administer. Thus, to combat a widely spreading disease in the community, oral drugs are the
most preferred.

There is no treatment or vaccine approved for Ebola BDBV at present. NV-387 Oral Gummies is
the only oral drug product in clinical trials, to the best of our knowledge, underscoring its importance for
fighting the current Ebola BDBV epidemic, and future epidemics.
The same drug product, NV-387 Oral Gummies, is also in a Phase II clinical trial for the
treatment of Mpox (Monkeypox) in DRC.

NV-387 is a novel, revolutionary broad-spectrum antiviral that is poised to change the way
humanity treats viral infections.

ABOUT NANOVIRICIDES
NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating
special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates
and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of
TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development
of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar
diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several
licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from
TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment
of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox
infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot
project an exact date for filing an IND for any of its drugs because of dependence on a number of external
collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical
trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate
remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir
encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA
approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable.
Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and
NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital
Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform
technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour
licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several
drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases:
Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes
Page 2 of 4Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue
viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The
Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful.
As is customary, the Company must state the risk factor that the path to typical drug development of any
pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts
by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would
show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this
time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful
pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation
regarding future events. Actual events could differ materially and substantially from those projected herein and
depend on a number of factors. Certain statements in this release, and other written or oral statements made by
NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forwardlooking statements since they involve known and unknown risks, uncertainties and other factors which are, in some
cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no obligation to publicly update or revise these
forward-looking statements for any reason, or to update the reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new information becomes available in the future. Important
factors that could cause actual results to differ materially from the company’s expectations include, but are not
limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the
company from time to time with the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such factors, they may include the following:
demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to
the indications we are seeking; the successful commercialization of our product candidates; and market acceptance
of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research
findings including clinical trials as the customary research usage and do not indicate evaluation of safety or
effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug”
application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and
Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines
Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”.
WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
[email protected]
Public Relations Contact:
[email protected]
Source: NanoViricides, Inc.

Release – Enterprises Empower AI Agents for Bounded Tasks

Posted on by [email protected]

10/27/2026

STAMFORD, Conn.–(BUSINESS WIRE)– Enterprises are using agentic AI to redistribute work between people and machines, giving it defined operational responsibilities while keeping humans in the loop, according to two new global research reports published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

The 2026 ISG Provider Lens® Agentic AI Services report finds that the technical capabilities of agents are progressing faster than companies are delegating responsibility to them. In most organizations, it is more common for agentic AI platforms to coordinate and perform defined tasks than to independently own consequential processes. This measured approach reflects concerns about accountability, permissions, security and operational risk in areas where technology can alter records or trigger actions.

“Organizations are focusing on work that intelligent platforms can perform reliably within defined limits,” said Steve Hall, chief AI officer, ISG. “The goal is allocation of responsibility between machines and people, with safeguards that preserve accountability for consequences. With clear operating conditions, companies can delegate responsibility to AI without exceeding acceptable business limits.”

The 2026 ISG Provider Lens® Agentic AI Services — Specialists report finds that specialist providers are advancing from isolated task agents toward multi-step workflows and multi-agent orchestration. They are industrializing delivery through libraries of reusable agents and embedding governance controls throughout the lifecycle of an agent rather than treating governance as a checkpoint.

Before assigning responsibilities to agents, enterprises are assessing whether decisions are bounded, outcomes are observable and exceptions are manageable. Multi-step processes with clear operating parameters are the strongest candidates for giving AI greater agency. The objective is to reduce human effort and handoffs across workflows while shortening cycle times and making organizations more responsive.

As more responsibility is delegated to AI agents, humans’ roles are shifting toward validation, approvals, exception handling and supervision. Authentication, audit trails, thresholds and escalation paths establish the conditions for permitting actions by agents and determining when responsibility returns to people. Enterprises are imposing rules and policy constraints to limit unexpected results. While 79 percent of enterprises plan to increase AI technology spending, improved governance is the most significant change companies say they would make based on their experience so far, ISG says.

“The real measure of agentic AI is not an individual agent’s sophistication, but its ability to move work forward reliably across the enterprise,” said Gowtham Kumar Sampath, ISG principal analyst and lead author of the report. “That requires dependable connections among systems, clear responsibilities and outcomes that can be observed at each step of a workflow.”

The reports also explore other trends in agentic AI services, including the increasing importance of validation, recovery and escalation when actions produce unexpected results and the growing demand for controls on agent access to tools, applications and data.

For more insights into the agentic AI-related challenges faced by enterprises, along with ISG’s advice for addressing them, see the ISG Provider Lens Focal Points briefing here.

The Agentic AI Services report evaluates 60 large and midsize providers across two quadrants: Agentic AI Development and Deployment Services — Large Providers and Agentic AI Development and Deployment Services — Midsize Providers.

The report names Accenture, Accion Labs, Apexon, Ascendion, Atos, Birlasoft, Brillio, Capgemini, Cognizant, Cybage, DXC Technology, EXL, Firstsource, HCLTech, Hexaware, IBM, Infosys, Konecta, NTT DATA, Persistent Systems, Softtek, Sutherland, TCS, Trigent, Unisys and Virtusa as Leaders in one quadrant each.

In addition, Genpact and HTC Global Services are recognized as Rising Stars — companies with a “promising portfolio” and “high future potential” by ISG’s definition — in one quadrant each.

The Agentic AI Services― Specialists report evaluates 21 providers in one quadrant: Agentic AI Development and Deployment — Specialist Providers.

The report names 66degrees, Fractal Analytics, Lingaro, Network Science, Quantiphi, Straive, Tiger Analytics, Tredence and Version 1 as Leaders in the quadrant.

In addition, Sigmoid is recognized as a Rising Star — a company with a “promising portfolio” and “high future potential” by ISG’s definition — in the quadrant.

In the area of customer experience, HCLTech, Persistent Systems and 66Degrees are named the global ISG CX Star Performers for 2026 among large, midsize and specialist Agentic AI Services providers, respectively. HCLTech, Persistent Systems and 66Degrees earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.

Customized versions of the reports are available from Accion Labs, Akkodis, Ascendion, Atos, DXC Technology, EXL, Firstsource, Hexaware, Mindsprint, Orion Innovation, Tiger Analytics, Tredence, Unisys, Version 1 and Virtusa.

The 2026 ISG Provider Lens Agentic AI Services report is available to subscribers or for one-time purchase on this webpage. The Agentic AI Services — Specialists report is available here.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data and research, in-depth knowledge and governance of provider ecosystems, and the expertise of its 1,500 professionals worldwide working together to help clients maximize the value of their technology investments.Source: Information Services Group, Inc.

Release – T3 Defense Enters Agreement to Acquire KeepZone AI

Posted on by [email protected]

Oct 27, 2026

NEW YORK and NETANYA, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) — T3 Defense Inc. (Nasdaq: DFNS) (“T3 Defense” or the “Company”), a defense company that acquires and operates mission-critical defense businesses, today announced that it has entered into a definitive stock purchase agreement to acquire 100% of KeepZone AI Inc. (“KeepZone”), a homeland security technology distribution, integration, and marketing company, from Nexera Technologies Ltd. (Nasdaq: NEXR) (“Nexera”). Following the closing, KeepZone is expected to serve as T3 Defense’s dedicated homeland security (HLS) marketing, sales and business development platform, extending the Company’s commercial reach to critical infrastructure, law enforcement, public safety, and border security customers in Israel and international markets.

T3 Defense Inc.

KeepZone adds a dedicated sales and business development capability to T3 Defense’s portfolio of engineering and manufacturing subsidiaries, bringing an experienced business development team, a U.S.-incorporated commercial entity, and representation agreements with homeland security technology providers that allow it to offer customers integrated, multi-layer security solutions. T3 Defense intends to use KeepZone’s sales channels to introduce its subsidiaries’ products alongside KeepZone’s existing portfolio, creating cross-selling opportunities and a broader offering for customers.

KeepZone markets, distributes, and integrates technologies for both its proprietary VocentraAI voice-analysis platform and products from its partners, including Scanary, SeeTrue, STI, RT LTA Systems, BeeSense, ParaZero, ZorroNet, VELQOR, SensorzTech and Skyline Software Systems. KeepZone combines these capabilities into coordinated security solutions for critical infrastructure and other homeland security applications.

“Our subsidiaries build mission-critical defense systems; KeepZone brings a dedicated sales platform to introduce those products to additional homeland security customers,” said Menny Shalom, Chairman and Chief Executive Officer of T3 Defense. “This acquisition will allow us to expand our commercial reach while providing us with a U.S. presence and active channels in North America, Latin America and the Gulf. We structured the transaction so that a majority of the potential consideration is contingent on KeepZone generating post-closing net profit, aligning the acquisition with our disciplined approach to capital allocation.”

“KeepZone was built to connect homeland security technologies with the customers who need them,” said Alon Dayan, Chief Executive Officer of KeepZone. “Joining T3 Defense adds a portfolio of engineered defense products that we can bring to our customer and partner relationships, so we can offer them a broader, integrated solution set from a single partner.”

Transaction Details

Initial consideration is $1.0 million, payable at closing in newly issued common stock (and, to the extent required by a 4.9% beneficial ownership limitation, pre-funded warrants), priced at the average closing price of T3 Defense common stock for the five trading days preceding closing. Nexera is also eligible for an earn-out equal to 50% of KeepZone’s standalone net profit generated during the 24 months following the closing, calculated on the first $10.0 million of net profit and therefore capped at $5.0 million, payable in cash. The seller is also entitled to additional shares of T3 Defense common stock if 6 months after closing the stock price is less than the price on closing. KeepZone is being acquired without any debt or liability. Closing is expected within 60 days of the signing of the stock purchase agreement, subject to customary closing conditions, including Nasdaq notification regarding the issuance of additional shares and certain third-party consents. Additional details will be included in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission (SEC).

About KeepZone AI Inc.
KeepZone AI Inc. is a homeland security technology company that markets, integrates and supports a multi-vendor portfolio of screening, surveillance, counter-UAS, AI analytics and unmanned aerial solutions for critical infrastructure, government and high-security environments. For more information, visit www.KeepZone.ai.

About T3 Defense Inc.
T3 Defense Inc. (Nasdaq: DFNS) is a defense company that acquires and operates mission-critical defense businesses involved in national security programs. It focuses on manufacturers with strong customer relationships and solid order backlogs, often capacity- and resource-constrained, in specialized areas such as drones and autonomous vehicles, counter-drone systems, advanced manufacturing, tactical robotics, and AI software and system integration. Through disciplined acquisitions, centralized capital and strategy, and decentralized day-to-day operations, T3 Defense aims to strengthen essential defense capabilities and build long-term value. For more information, visit www.t3dfns.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the anticipated closing and timing of the acquisition of KeepZone; the expected benefits of the acquisition, including cross-selling and commercial opportunities; the potential earn-out; KeepZone’s representation and distribution relationships; and the Company’s growth and acquisition strategy. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially, including: the risk that closing conditions, including Nasdaq notification and third-party consents, are not satisfied or that the transaction does not close; the risk that KeepZone’s representation or distribution agreements are terminated, not renewed or not consented to; the absence of any assurance that KeepZone will generate revenue or profit or that any earn-out will become payable; dilution from the issuance of shares and warrants; integration risks; defense and homeland security procurement timing and funding; customer concentration; competitive and geopolitical conditions, including conditions in Israel; the Company’s liquidity and capital resources; the Company’s ability to maintain compliance with Nasdaq listing requirements; and other risks described in the Company’s filings with the SEC, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contact Us:
T3 Defense Inc.
575 5th Avenue
New York, NY 10017
[email protected]
www.t3dfns.com

Investor Relations
The Equity Group Inc.
Lena Cati
[email protected]
+1 212 836-9611

Val Ferraro
[email protected]
+1 212 836-9633

Release – Lucky Strike Entertainment Completes Transition of Bowlmor Locations to Lucky Strike

Posted on by [email protected]

10/27/2026

Bowlmor Cupertino becomes Lucky Strike Cupertino, carrying forward the legacy of the brand that started it all

RICHMOND, Va.–(BUSINESS WIRE)– Lucky Strike Entertainment (NYSE: LUCK), one of the world’s premier owner-operators of location-based entertainment destinations, announced today that Bowlmor Cupertino has been rebranded as Lucky Strike Cupertino, marking the transition of the company’s final operating Bowlmor location. The milestone celebrates the brand that first turned bowling into a night out and marks the next chapter for a company that continues to grow as more people rediscover the lanes. The new Lucky Strike Cupertino location arrives just in time for holiday party season, giving Bay Area companies, teams and groups a new destination for year-end celebrations.

Bowlmor Lanes opened in New York City’s Greenwich Village in the 1930s and became a beloved neighborhood institution. In 1997, Thomas Shannon acquired Bowlmor and reimagined what a bowling center could be, adding upscale food and cocktails, music, lighting, and lounge-style lanes. The concept invented bowling as entertainment, turning a classic pastime into a pop culture hotspot complete with A-listers such as Sarah Jessica Parker, Jimmy Fallon, and Al Pacino. That vision became the foundation for Lucky Strike Entertainment’s growth into a company with more than 360 locations across North America, spanning bowling, amusements, water parks, and family entertainment centers. It’s fitting that Bowlmor’s final chapter unfolds in Cupertino, a city known worldwide for reinventing entire categories. Today, Lucky Strike carries Bowlmor’s spirit and Shannon’s vision forward in every center.

“Bowlmor is where it all began. We set out to prove that bowling could be the best day or night out in the city, and that idea has grown into something bigger than we ever imagined,” said Thomas Shannon, Founder and CEO of Lucky Strike Entertainment. “Bringing Bowlmor Cupertino under the Lucky Strike name isn’t an ending. It’s a celebration of everything Bowlmor started and a sign of how much bowling continues to grow.”

The rebrand comes as bowling enjoys renewed momentum, with league participation rising every year and nearly 70M people bowling on average each year. Lucky Strike Cupertino offers guests state-of-the-art bowling lanes, elevated food and beverage options, a vibrant arcade and immersive Bay Area entertainment experiences, including holiday parties and group celebrations.

For more information on Lucky Strike Cupertino, visit LuckyStrikeEnt.com, or follow along on social at @luckystrikeent. For information on parties and packages, visit here.

About Lucky Strike Entertainment:
Lucky Strike Entertainment is one of the world’s premier location-based entertainment platforms. With over 360 locations across North America, Lucky Strike Entertainment provides experiential offerings in bowling (Lucky Strike, Bowlero, AMF), amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Lucky Strike Entertainment, please visit IR.LuckyStrikeEnt.com.

Media:
[email protected]

Source: Lucky Strike Entertainment Corporation

Fed Rate Decision Wednesday: Why Small-Cap Stocks Face a Critical Test as Inflation Pressures Build

Posted on by [email protected]

The Federal Reserve is preparing to announce its latest interest rate decision Wednesday, October 28, as investors assess whether persistent inflation and elevated borrowing costs could create additional challenges for U.S. stocks, particularly smaller companies that depend heavily on access to capital.

The Federal Open Market Committee began its two-day policy meeting Tuesday, with economists broadly expecting policymakers to maintain the benchmark federal funds rate at its current range of 3.75% to 4.00%. While an immediate rate increase appears unlikely, attention is shifting toward the central bank’s outlook for December and whether inflation could require additional monetary tightening.

The upcoming announcement arrives at a sensitive moment for financial markets. Inflation remains above the Federal Reserve’s 2% target, while higher energy prices and persistent price pressures have complicated expectations for the direction of interest rates.

For investors, the most important development may not be Wednesday’s decision itself, but what Federal Reserve Chair Kevin Warsh communicates about the central bank’s willingness to keep borrowing costs elevated or raise rates further.

Market expectations currently favor an unchanged policy rate this week. However, interest rate futures indicate investors are assigning considerably greater probability to an increase at the Fed’s December meeting, underscoring concerns that inflation may remain difficult to control.

The prospect of sustained higher interest rates carries particular significance for small-cap companies. Unlike many large corporations with substantial cash reserves and established access to debt markets, smaller businesses frequently depend on bank financing, revolving credit facilities, and capital markets to support expansion and operations.

Higher interest rates can increase debt servicing expenses, reduce profitability, and make new investment projects more expensive. Companies with significant refinancing requirements may face additional pressure as existing debt matures and must be replaced at higher borrowing costs.

These conditions can also influence equity valuations. When Treasury yields rise, investors may demand higher returns from riskier assets, potentially placing downward pressure on stocks with earnings expected further into the future.

The Russell 2000 Index, a widely followed benchmark for smaller publicly traded U.S. companies, is particularly sensitive to changes in financing conditions and expectations for economic growth.

For emerging biotechnology companies, elevated interest rates can make equity financing more challenging and increase the importance of maintaining sufficient cash to fund clinical trials and regulatory development. Smaller industrial and consumer businesses may face a different combination of pressures, including financing expenses, higher input costs, and changes in customer demand.

Meanwhile, companies in energy and materials must balance borrowing costs against the effects of commodity prices, which can influence both revenue expectations and inflation trends.

The Federal Reserve’s decision also comes as longer-term Treasury yields remain elevated. The benchmark 10-year Treasury yield has approached 5%, adding pressure to borrowing costs across the economy, including mortgages and corporate financing.

Wednesday’s announcement could therefore influence investor sentiment even if policymakers leave the benchmark rate unchanged. A statement emphasizing persistent inflation or the possibility of further tightening could push Treasury yields higher, while signs of greater confidence in inflation moderation could provide some relief to rate-sensitive sectors.

Investors will also monitor any disagreements among Federal Reserve officials, particularly whether policymakers favoring tighter monetary policy signal growing concern about inflation.

For small-cap investors, the central question is whether the Federal Reserve can bring inflation under control without creating additional financial strain for businesses that rely on affordable c

VivoPower International PLC (VIVO) – Advancing Mo i Rana Development and Sovereign AI Strategy

Posted on by [email protected]


Tuesday, October 27, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Construction mobilized at Mo i Rana. On October 12, 2026, VivoPower announced the start of construction for the initial 40MW AI data center at its Mo i Rana facility in Norway. While a definitive lease agreement has not yet been announced, the company confirmed that it has selected a global AI industry leader as its preferred tenant, with the facility’s design and construction tailored to the prospective customer’s requirements.

Existing operations maintained during construction. VivoPower has engaged local contractors to complete site preparation and structural works ahead of the specialized mechanical and electrical fit-out. Under the original development plan, construction will proceed on adjacent land while existing Bitcoin mining and grid-balancing operations continue. After the mining lease expires in June 2027, the existing power capacity is earmarked for AI applications, with an additional 40MW development planned thereafter.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Star Equity Holdings, Inc. (STRR) – A Tuck-in; Updated Model

Posted on by [email protected]


Tuesday, October 27, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Tuck-in. Yesterday, Star Equity announced that its Energy Services division acquired a privately held Vernal, Utah-based machine shop that provides repair, rebuild, and machining services for well fishing tools, drill pipe, and other drilling equipment. The transaction closed on October 23, 2026, and the shop will work alongside Alliance Drilling Tool’s (ADT) existing Vernal operation. No financial details were provided.

Additional Detail. Adding these in-house capabilities makes ADT’s Vernal operation a full-service location. ADT can support customers across more of the tool life cycle while gaining more direct control over service quality and turnaround time. The expanded capabilities also position ADT to more actively pursue oil and gas drilling work in the Uinta Basin, as well as mining and geothermal opportunities across the region.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Another Homebuilder Deal

Posted on by [email protected]


Tuesday, October 27, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Deal. Hot on the heels of the Maronda Homes announcement, SKYX Platforms revealed an agreement to supply 60,000 units of its smart home technologies for over 700 homes to be built by Home Creations. The units are expected to be provided over the next 12 months. We believe these are the first of many agreements to be awarded in the future for SKYX products in the home builder vertical.

Home Creations. Founded in 1981, Home Creations is a family-founded homebuilder serving Oklahoma and the Houston, Texas, market. Significantly, Home Creations combines energy-efficient construction with smart home features. The firm’s Oklahoma City homes are nearly 53% more energy-efficient than typical new homes and include Deako smart lighting, a smart thermostat, smart locks, and an app-enabled garage door. Every home is HERS-verified by a certified RESNET energy rater and backed by a 10-year structural warranty.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Resolution Minerals Ltd (RML) – Golden Gate North Gold Zone Expands

Posted on by [email protected]


Tuesday, October 27, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Drilling expands the gold zone. Resolution Minerals reported additional drill results from Golden Gate North at its 100%-owned Horse Heaven project in Idaho, confirming gold mineralization over an area measuring at least 500 meters along strike, 200 meters in width, and 300 meters in depth. The results expand the known mineralized footprint and strengthen the potential for a sizable near-surface gold system.

Broad mineralized intervals. Three newly reported drill holes intersected extensive gold mineralization beginning at the surface, including 324 meters grading 0.49 grams per tonne (g/t) gold and 322 meters grading 0.37 g/t gold. Although grades remain relatively modest, the continuity and scale of mineralization are encouraging and support further evaluation of potential bulk tonnage mineralization.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Eledon Pharmaceuticals (ELDN) – Phase 2 BESTOW Analysis Shows Improved Quality Of Life and Reduced Symptom Burden

Posted on by [email protected]


Tuesday, October 27, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Data Presentation On Quality of Life and Symptoms. Eledon presented data from the Phase 2 BESTOW trial at the American Society of Nephrology Annual Kidney Week 2026 meeting. The presentation compared patients receiving tegoprubart with those receiving tacrolimus, showing improvements in quality of life and reductions in symptom burden at 12 months. We believe these findings support prior data on efficacy, safety, and tolerability.

Patient Evaluations. Data from two accepted clinical evaluations, MTSOSD-59R and KDQOL-SF, showed substantial, lasting improvements in quality of life and reductions in transplant-related side effects. We see these patient-reported outcomes as consistent with prior reductions in BPAR (Biopsy-Proven Acute Rejection), improvements in eGFR, and improvements in factors that contribute to long-term graft failure.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – Strong Third Quarter Results Reinforce Constructive 2027 Outlook

Posted on by [email protected]


Tuesday, October 27, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Third Quarter Financial Results. Alliance Resource Partners reported third-quarter 2026 revenue of $603.0 million, up 5.5% year-over-year and 9.3% sequentially. Net income attributable to ARLP increased 46.8% to $139.6 million, or $1.08 per unit, compared with $0.73 a year ago and $0.61 in the second quarter. Adjusted EBITDA attributable to ARLP increased 26.3% to $233.9 million, reflecting stronger coal operations and record oil and gas royalty contributions.

Operating Performance Strengthens. Coal sales increased 7.4% year-over-year to 9.35 million tons, supported by resumed production at Hamilton and strong performance at River View and Tunnel Ridge. Segment Adjusted EBITDA expense per ton decreased 13.1% to $35.64, contributing to an 18.6% increase in Coal Operations Segment Adjusted EBITDA to $186.8 million. The AllDale III and IV acquisition contributed to record oil and gas royalty production of 1.45 million barrels of oil equivalent, while attributable segment Adjusted EBITDA increased 61.4% to $43.6 million.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

1-800-Flowers.com (FLWS) – Transformation Efforts Progressing; Financial Flexibility Remains a Focus

Posted on by [email protected]


Tuesday, October 27, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Additional cost savings identified. The company highlighted $50 million in annualized run-rate cost savings achieved ahead of schedule in fiscal 2026 and identified an additional $15 million to $20 million in potential annualized savings for fiscal 2027. We believe these initiatives could support a recovery in profitability, although the timing and extent of the EBITDA contribution remain uncertain.

Focus on financial flexibility. The company highlighted an amendment to its credit agreement that extends covenant relief and provides greater flexibility in using asset-sale proceeds. In addition, the company is evaluating financing alternatives, including potential debt or equity transactions and nonstrategic asset divestitures.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.